- In February 2024, BIOTRONIK launched the Micro Rx catheter, an innovative rapid exchange microcatheter designed to improve guidewire support during percutaneous coronary interventions (PCI). Manufactured by IMDS (Interventional Medical Device Solutions) and exclusively distributed by BIOTRONIK, this advanced device strengthens BIOTRONIK’s U.S. portfolio, which also includes the NHancer Rx, TrapIT, and ReCross catheters. The introduction of the Micro Rx catheter is expected to enhance BIOTRONIK’s competitive position in the angiographic catheter market by offering clinicians improved procedural efficiency and support in complex coronary interventions
- In October 2022, the HELIOSTAR Balloon Ablation Catheter received indication for cardiac ablation and catheter-based electrophysiological mapping of the atria when used with a compatible multi-channel RF generator. This advancement enhances the product’s clinical utility, positioning it as a key device in the growing cardiac electrophysiology market
- In February 2022, Teleflex secured FDA clearance for expanded indications of its specialty catheter and coronary guidewire, specifically for crossing chronic total occlusions during percutaneous coronary interventions (PCI). This approval broadens Teleflex’s market reach by enabling more complex coronary procedures, strengthening its position in the angiographic catheter segment
- In July 2021, Philips announced the successful use of its real-time 3D intracardiac echocardiography catheter in a minimally invasive heart procedure, marking a significant technological breakthrough. This innovation is expected to boost Philips’ market presence by offering clinicians enhanced imaging capabilities, improving procedural accuracy and patient outcomes in cardiac interventions
